Senores Pharmaceuticals Limited, headquartered in Ahmedabad, has started off the financial year 2026 with impressive performance, showcasing substantial growth in both regulated and emerging markets. The company, known for its specialized focus on complex products, recently disclosed its unaudited results for the quarter ending June 30, 2025. In regulated markets, Senores witnessed a remarkable 69% year-on-year revenue increase, reaching Rs. 90 crore, accompanied by a notable EBITDA margin of 35.5%. The company’s portfolio in these markets includes 24 proprietary commercial products, 70 approved ANDAs, 57 pipeline products with 37 Competitive Generic Therapy (CGT) opportunities, and 27 CDMO/CMO commercial products supported by an additional 53 in the pipeline. Emerging markets also demonstrated strong growth, with revenue hitting Rs. 29 crore, marking a 32% surge from the previous year. Senores currently operates in over 40 countries, offering 308 registered products and 719 products under registration. Managing Director, Swapnil Shah, expressed satisfaction with the company’s performance, highlighting the launch of two own ANDA products and the acquisition of four new ANDA approvals in regulated markets during the quarter.
Shah emphasized Senores’ competitive edge in the US market, particularly its ability to serve government channels alongside the retail segment and its local manufacturing and supply capabilities for controlled substances. The company’s CDMO/CMO segment is also on an upward trajectory, with new contracts secured and increased business from existing clients, providing strong visibility for the future. Senores’ evolving product portfolio and strategic market approach in emerging markets are driving improved profitability, with the branded generics segment experiencing significant growth. The company aims to establish a nationwide presence in India by the end of FY26. Noteworthy achievements in the quarter included a positive operating cash flow of Rs. 11 crore, indicating a positive transformation in the business that promises sustained growth in the medium to long term. Shah outlined three key focus areas for the company’s future growth: expanding the ANDA portfolio in regulated markets, scaling up the CDMO/CMO segment, and enhancing the portfolio and profitability in emerging markets. Senores Pharmaceuticals, a global research-driven pharma firm, specializes in developing and manufacturing a diverse range of products across therapeutic areas for markets including the US, Canada, and over 40 emerging economies.
Read more from pharmabiz.com